Welcome to our dedicated page for Colgate Palmolive Co SEC filings (Ticker: CL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Colgate-Palmolive Company filings document a global consumer-products issuer with NYSE-listed common stock and registered debt securities. The company's 8-K reports cover earnings releases, the Strategic Growth and Productivity Program, reportable operating segment realignments, senior-note activity, debt-listing changes and governance events such as director elections and officer succession.
Proxy materials describe board elections, executive compensation, shareholder voting matters and strategic priorities tied to growth, efficiency and cash flow. The filings also identify registered securities, including common stock and multiple note series, and provide formal records for shareholder meetings, compensation arrangements and changes affecting listed note classes.
Colgate-Palmolive Chief Human Resources Officer Sally Massey reported stock-based compensation activity tied to performance awards. She acquired 16,805 shares of Common Stock at no cost from the vesting of previously granted performance-based restricted stock units earned under the company’s incentive plan. To cover tax obligations from this vesting, 8,206 shares were disposed of through a tax-withholding transaction at $97.10 per share, rather than an open-market sale. After these transactions, she directly owns 22,384 shares of Common Stock and indirectly holds 8,111 shares through the issuer’s 401(k) plan trustee.
Colgate-Palmolive Chief Financial Officer Stanley J. Sutula III reported equity compensation activity involving the company’s common stock. He acquired 38,678 shares on February 23, 2026 through the vesting of previously granted performance-based restricted stock units earned under the incentive compensation plan.
On the same date, 19,746 shares were disposed of to cover tax withholding related to this vesting, rather than through an open-market sale. After these transactions, he held 74,320 shares directly and 328 shares indirectly through the issuer’s 401(k) plan trustee.
Colgate-Palmolive COO Panagiotis Tsourapas received 25,742 shares of Common Stock on February 23, 2026 from vesting of performance-based restricted stock units earned under the company’s incentive plan. No cash changed hands for this award.
On the same date, 13,081 shares were withheld at $97.10 per share to cover related tax liabilities. After these transactions, he directly holds 21,629 shares, plus 4,568 shares through the issuer’s 401(k) plan trustee and 62,240 shares held by a trust.
Colgate-Palmolive Chairman, President & CEO Noel R. Wallace reported equity award activity in company stock. On February 23, 2026, he acquired 136,710 shares of Common Stock at $0.00 per share through vesting of previously granted performance-based restricted stock units earned under the incentive compensation plan. On the same date, 68,252 shares at $97.10 per share were withheld to cover tax obligations related to this vesting, a non-open-market disposition. Following these transactions, he directly owned 361,921 shares of Common Stock. He also had indirect holdings of 54,281 shares through the issuer's 401(k) plan trustee, 52,000 shares via a spouse trust, and 335 shares via another trust.
Colgate-Palmolive Company files its annual report describing a global consumer products business focused on Oral, Personal and Home Care and Pet Nutrition. In 2025, Oral Care, Personal Care and Home Care represented 44%, 17% and 16% of worldwide net sales, with Pet Nutrition at 23%.
The company highlights strong international exposure, with about two‑thirds of net sales from outside the United States and approximately 33,600 employees in over 100 countries as of December 31, 2025. It emphasizes brand strength in toothpaste, liquid hand soap, household cleaners and specialty pet food, supported by significant advertising and digital demand generation.
Key themes include heavy reliance on Walmart for about 11% of 2025 net sales, exposure to commodity and logistics cost volatility, and extensive discussion of geopolitical, cybersecurity, regulatory, climate and sustainability risks. The report also notes a new three‑year Strategic Growth and Productivity Program, a $5 billion share repurchase authorization approved in March 2025 and a non‑cash, after‑tax goodwill and intangible asset impairment charge of $794 million in the skin health business.
Tsourapas Panagiotis reported multiple insider transaction types in a Form 4 filing for CL. The filing lists transactions totaling 150,000 shares at a weighted average price of $85.99 per share. Following the reported transactions, holdings were 19,938 shares.
Colgate-Palmolive common stock holder plans Rule 144 sale of 15,000 shares of common stock through Merrill Lynch on the NYSE, with an aggregate market value of 1,467,111.44. The issuer reports 806,064,942 common shares outstanding.
The 15,000 shares were acquired on 02/12/2026 via an exercise of employee stock options in a broker-assisted cashless exercise, with payment also on 02/12/2026. The filing also lists a prior sale of 35,000 common shares on 02/11/2026 by Panagiotis Tsourapas for gross proceeds of 3,311,325.24.
Colgate-Palmolive Chief Growth Officer Hazlin John exercised stock options for 20,989 shares of common stock at $76.41 per share on February 10, 2026, then sold 20,989 shares at a weighted average price of $94.2499 per share. A portion of the sale proceeds was delivered to the company to pay the option exercise price and related tax withholding. After these transactions, John directly owned 17,645 shares and indirectly held 5,452 shares through the issuer's 401(k) plan trustee.
A shareholder associated with Colgate-Palmolive Company has filed a notice to sell 35,000 shares of common stock on the NYSE through Merrill Lynch. The planned sale has an aggregate market value of $3,311,325.26.
The shares were acquired on 02/11/2026 through the exercise of employee stock options via a broker-assisted cashless exercise, with payment also dated 02/11/2026. Colgate-Palmolive had 806,064,942 shares outstanding of common stock at the time referenced.
Colgate-Palmolive executive Malcolm Gregory reported an employee stock option exercise and related share sale. On February 6, 2026, he exercised options for 12,747 shares of common stock at $76.41 per share under the company’s incentive compensation plan.
That same day, he sold 12,747 shares of Colgate-Palmolive common stock in market transactions at a weighted average price of $94.9103 per share, with individual trades ranging from $94.79 to $95.01. After these transactions, he directly owned 11,879 shares and held an additional 8,554 shares indirectly through the issuer’s 401(k) plan trustee.